Document 0830
 DOCN  M9590830
 TI    An assay for HIV infection of cultured human cervix-derived cells.
 DT    9509
 AU    Phillips DM; Tan X; Pearce-Pratt R; Zacharopoulos VR; Population
       Council, New York, NY 10021, USA.
 SO    J Virol Methods. 1995 Mar;52(1-2):1-13. Unique Identifier : AIDSLINE
       MED/95286730
 AB    There is a critical need to develop new strategies to prevent sexual
       transmission of HIV. Condoms have limited acceptance, and a vaccine may
       not be available for many years. A vaginal formulation could provide an
       alternative method if a compound that inhibits sexual transmission of
       HIV can be identified or synthesized, and if this agent can be
       formulated for vaginal use. In this report we describe an infection
       assay for testing compounds that may be useful in a vaginal formulation.
       This assay system utilizes a cell line (ME-180) derived from the human
       cervix which, on the basis of morphological features, is an appropriate
       model of female and male genital and urinary tract epithelia. These
       cells can be productively infected with HIV upon exposure to
       HIV-infected T-cell lines. Blocking experiments can be readily carried
       out in this model because in this p24 ELISA assay system the quantity of
       virus released by the infected epithelium over a 24-h period is 40 times
       background.
 DE    Cell Line  Cell Survival/DRUG EFFECTS  Cells, Cultured  Cervix
       Uteri/*VIROLOGY  Epithelium/DRUG EFFECTS/ULTRASTRUCTURE/VIROLOGY  Female
       Human  HIV/*ISOLATION & PURIF/PHYSIOLOGY/ULTRASTRUCTURE  HIV
       Infections/*DIAGNOSIS/TRANSMISSION  Lymphocytes/CYTOLOGY/DRUG EFFECTS
       Microscopy, Electron  Mitomycin C/PHARMACOLOGY  Support, Non-U.S. Gov't
       Support, U.S. Gov't, P.H.S.  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).